LEPROSY (Hansen’'s disease)

By Gary M. White, MD


Leprosy is a chronic infection by Mycobacterium leprae, which has a preference for the skin and peripheral nerves.

Leprosy in the United States

According to the CDC, 178 cases of leprosy were reported in the US in 2015. Cases from Hawaii, Texas, California, Louisiana, New York and Florida made up 72% of cases. Contact with the armadillo is a risk factor for development of leprosy and cases have been reported in the US in Texas and Florida.


The typical lesion in the tuberculoid type is a large annular erythematous plaque with an involuting, hypopigmented, anesthetic center. Nerve enlargement (e.g. greater auricular, superficial peroneal) with muscle atrophy may occur. In lepromatous leprosy, nodular infiltration of the face and ears and elsewhere is characteristic. The eyebrows may be progressively lost. Alopecia may occur in the scalp as well [Int J Trichol 2015;7:74-6].

The histoid type of LL presents as multiple skin-colored soft to firm papulonodules, subcutaneous nodules, or fixed plaques. Lesions resembling neurofibromatosis and molluscoid lesions of histoid leprosy are also known. The underlying skin is usually normal.

Tremendous mutilating deformities of the hands and feet may occur in chronic disease. Without the ability to feel pain, injuries occur to digits from simple everyday activities. Trauma, ulcerations and infections lead to scarring and loss of tissue. Fingers and toes become shortened and deformed.

Slit smear for diagnosis may be performed on, for example, the earlobes. Application of a suitable topical local anesthetic before the procedure can decrease the pain. All family members should be evaluated for hypopigmented and anesthetic macules.


The latest recommended treatment guidelines for multi-drug therapy should be consulted. In the past, the following have been recommended.

For paucibacillary disease: rifampicin (600 mg monthly, supervised) plus dapsone (100 mg/day), both for 6 months.

For multibacillary disease: rifampicin (600 mg) and clofazimine (300 mg) monthly, supervised, plus dapsone (100 mg/day) and clofazimine (50 mg/day) for 2 years preferably to smear negativity.

Additional Pictures

Infiltrated plaques on the back of a man who frequently visited Mexico.
Leprosy Leprosy

Lepromatous Leprosy, Histiocytoid type. Courtesy James Steger, MD
Lepromatous Leprosy, Histiocytoid type

Infiltrated plaques of the face. Courtesy Steven H Goldberg, MD

Borderline Tuberculoid Leprosy. Courtesy James Steger, MD
Borderline Tuberculoid Leprosy


Home | FAQs | Use of Images | Privacy Policy | Contact

It is not the intention of RegionalDerm.com to provide specific medical advice, diagnosis or treatment. RegionalDerm.com only intends to provide users with information regarding various medical conditions for educational purposes and will not provide specific medical advice. Information on RegionalDerm.com is not intended as a substitute for seeking medical treatment and you should always seek the advice of a qualified healthcare provider for diagnosis and for answers to your individual questions. Information contained on RegionalDerm.com should never cause you to disregard professional medical advice or delay seeking treatment. If you live in the United States and believe you are having a medical emergency call 911 immediately.